AG真人官方

Cytokinetics to Announce Second Quarter Results On August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics鈥� senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics鈥� website at or directly at the following link: An archived replay of the webcast will be available via Cytokinetics鈥� website for six months.

About Cytokinetics

Cytokinetics聽is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.聽Cytokinetics聽is readying for potential regulatory approvals and commercialization of聽补蹿颈肠补尘迟别苍,听a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).聽Aficamten聽is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM.聽In addition,聽Cytokinetics聽is developing聽omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from聽补蹿颈肠补尘迟别苍,听for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit 聽and follow us on , , and .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the 鈥淎ct鈥�). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act鈥檚 Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics鈥� and its partners鈥� research and development activities of Cytokinetics鈥� product candidates. Such statements are based on management鈥檚 current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics鈥� business outlines in Cytokinetics鈥� filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics鈥� actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS庐 and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757